- Previous Close
2.1200 - Open
2.1400 - Bid --
- Ask --
- Day's Range
2.1400 - 2.1400 - 52 Week Range
1.7600 - 2.6800 - Volume
1,390 - Avg. Volume
0 - Market Cap (intraday)
5.386B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
7.64 - EPS (TTM)
0.2800 - Earnings Date Apr 24, 2025 - Apr 28, 2025
- Forward Dividend & Yield 0.15 (7.02%)
- Ex-Dividend Date Oct 15, 2024
- 1y Target Est
--
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical equipment, and healthcare products; and research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical services, health management, health maintenance, elderly care, etc.; and provides leasing and commercial, health, advertising, loading offloading, and warehouse services. It operates through retail chain pharmacy stores and retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
www.gybys.com.cn28,048
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GU5.F
View MorePerformance Overview: GU5.F
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GU5.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GU5.F
View MoreValuation Measures
Market Cap
5.22B
Enterprise Value
4.67B
Trailing P/E
9.73
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.37
Price/Book (mrq)
0.77
Enterprise Value/Revenue
0.49
Enterprise Value/EBITDA
7.55
Financial Highlights
Profitability and Income Statement
Profit Margin
4.48%
Return on Assets (ttm)
3.18%
Return on Equity (ttm)
9.73%
Revenue (ttm)
76.39B
Net Income Avi to Common (ttm)
3.42B
Diluted EPS (ttm)
0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
17.47B
Total Debt/Equity (mrq)
36.82%
Levered Free Cash Flow (ttm)
528.74M